CELLULAR AND GENE THERAPIES
Y. Hattori
N. Ohshima
Y.Taniguchi
Y. Iba
H. Kojima
M.Takahashi
K. Mihara
F. Putti
L. Roz
F. Murianni
G. Bertolini
M. Gentili
F. Zonca
M. Figini
E. Luison
F. D. de Braud
Марчелло Федерика Ди
F. De Santis
TL;DR
Anti-CD38-CAR-allogeneic gd T-cell therapy is expected to be a highly effective and feasible treatment for patients with relapsed and refractory myeloma as an off-the-shelf use.